A detailed history of Schonfeld Strategic Advisors LLC transactions in Day One Biopharmaceuticals, Inc. stock. As of the latest transaction made, Schonfeld Strategic Advisors LLC holds 47,380 shares of DAWN stock, worth $650,053. This represents 0.0% of its overall portfolio holdings.

Number of Shares
47,380
Previous 244,957 80.66%
Holding current value
$650,053
Previous $3.38 Million 80.44%
% of portfolio
0.0%
Previous 0.02%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$12.72 - $16.03 $2.51 Million - $3.17 Million
-197,577 Reduced 80.66%
47,380 $660,000
Q2 2024

Aug 14, 2024

BUY
$12.03 - $17.69 $86,724 - $127,527
7,209 Added 3.03%
244,957 $3.38 Million
Q1 2024

May 15, 2024

BUY
$13.56 - $17.46 $797,517 - $1.03 Million
58,814 Added 32.87%
237,748 $3.93 Million
Q4 2023

Feb 14, 2024

BUY
$9.68 - $15.37 $408,825 - $649,136
42,234 Added 30.9%
178,934 $2.61 Million
Q3 2023

Nov 14, 2023

BUY
$11.22 - $14.86 $237,662 - $314,764
21,182 Added 18.34%
136,700 $1.68 Million
Q2 2023

Aug 14, 2023

BUY
$11.74 - $14.47 $124,185 - $153,063
10,578 Added 10.08%
115,518 $1.38 Million
Q1 2023

May 15, 2023

SELL
$12.75 - $23.41 $134,640 - $247,209
-10,560 Reduced 9.14%
104,940 $1.4 Million
Q4 2022

Feb 14, 2023

BUY
$18.77 - $22.0 $1.73 Million - $2.03 Million
92,113 Added 393.86%
115,500 $2.49 Million
Q3 2022

Nov 14, 2022

SELL
$16.44 - $26.57 $278,049 - $449,378
-16,913 Reduced 41.97%
23,387 $468,000
Q2 2022

Aug 15, 2022

BUY
$5.72 - $17.9 $230,516 - $721,370
40,300 New
40,300 $722,000

Others Institutions Holding DAWN

About Day One Biopharmaceuticals, Inc.


  • Ticker DAWN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 73,461,104
  • Market Cap $1.01B
  • Description
  • Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric pa...
More about DAWN
Track This Portfolio

Track Schonfeld Strategic Advisors LLC Portfolio

Follow Schonfeld Strategic Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Schonfeld Strategic Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Schonfeld Strategic Advisors LLC with notifications on news.